Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease
- PMID: 22605906
- PMCID: PMC3351880
Roflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease
Figures
References
-
- Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS [American Thoracic Society/European Respiratory Society] position paper. Eur Respir J. 2004;23(6):932–946. - PubMed
-
- Williams DM, Bourdet SV. Chronic obstructive pulmonary disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York: McGraw-Hill Medical; p. 2008.
-
- Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 1999;160(3):893–898. - PubMed
-
- Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. (Updated 2011). Available at: www.gold-copd.org/uploads/users/files/gold_Re-port_2011_Jan21.pdf. Accessed February 2, 2012. - PubMed
-
- Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: Data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2000;160(11):1683–1689. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources